Yes, essentially, valuations are high. But the markets also see that there is a monetary easing cycle around the corner, so I think that is creating a push and pull. On top of that, we have huge promoter and private equity sales coming up.
Zydus Lifesciences shares fall 2% as firm acquires US-based Assertio Holdings for $166 million
Zydus Lifesciences’ shares dipped 2% after completing the $166.4 million acquisition of US-based Assertio Holdings Inc. The deal, finalized through a subsidiary, makes Assertio a